ReviewTheranostics2026
From bench to bedside: the promise and roadblocks of extracellular vesicle therapeutics.
Review in Theranostics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Exercise‑induced exosomal noncoding RNAs: Molecular signaling cascades in bone remodeling and translational applications in sports‑related bone injuries (Review).International journal of molecular medicine · 2026Review
- Smart and stimuli-responsive hydrogels for controlled exosome delivery in bone tissue engineering: from passive carriers to intelligent therapeutic platforms.Cell and tissue banking · 2026Review
- Extracellular Matrix-Based and Extracellular Matrix-Bioinspired Scaffolds for Extracellular Vesicle Delivery in Dental Pulp Regeneration: A Narrative Review.Biotech (Basel (Switzerland)) · 2026Review
- Review
- From pathophysiology to therapy: molecular mechanisms of stem cell and extracellular vesicle-mediated repair in diabetic peripheral neuropathy.Frontiers in cell and developmental biology · 2026Review
- Extracellular Vesicles for Therapeutic Applications: A Translational Framework Integrating Sources, Administration Routes, Indications, Quality Control, and Regulatory Systems.International journal of nanomedicine · 2026Review
- Mesenchymal Stem Cells Derived Extracellular Vesicles in Inflammatory Bowel Disease: Therapeutic Efficacy and Bioengineering Applications.International journal of nanomedicine · 2026Review
- Precision Engineering of Extracellular Vesicles as Programmable Carriers for mRNA Therapeutics.International journal of nanomedicine · 2026Review
- Extracellular Vesicle-Based Strategies for the Prevention of Chemotherapy-Induced Cardiotoxicity.Therapeutics and clinical risk management · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Extracellular vesicles (EVs) have transformed the landscape of precision therapeutics, owing to their intrinsic biocompatibility, capacity to transport biomolecules, and ability to cross biological barriers. Benefiting from these advantages, several EV-based therapeutic applications are currently under active development. However, most products remain at the preclinical stage due to significant translational challenges. In this review, we systematically outline these obstacles and highlight opportunities that can accelerate the clinical translation of EVs. We first identify core issues impeding clinical progress, such as difficulties in isolation, storage stability, precise characterization, biosafety evaluation, and quality control. After that, we examine emerging technologies designed to overcome these bottlenecks, including advanced bioreactors for large-scale production, microfluidic systems for high-purity separation, single-vesicle analysis technologies to address heterogeneity, and machine learning approaches that enhance standardization and support clinical decision-making. Finally, we discuss future directions focused on standardizing EV production, improving safety assessment, and ensuring regulatory compliance. By addressing current challenges and identifying promising pathways, this review aims to facilitate the translation of EV-based therapies from bench to bedside.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.